Natural and engineered ribonucleases as potential cancer therapeutics

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Ribonucleases (RNases) possess inherent cytotoxicity, making them candidates for anti-tumor drug development.
• Specific superfamilies, including RNase A and RNase T1, have demonstrated significant therapeutic promise.
• Onconase, an RNase derived from the Northern Leopard frog, is notably advanced in clinical trials.

Purpose of the Study:

• To discuss various strategies for exploiting the cytotoxic properties of RNases as anti-cancer agents.
• To elucidate the complex mechanisms underlying RNase-mediated cytotoxicity.
• To highlight the potential of RNases in cancer treatment.

Main Methods:

• Review of existing literature on RNase mechanisms and anti-tumor applications.
• Analysis of the general model for RNase cytotoxic action, including cellular uptake and RNA degradation.
• Discussion of factors influencing RNase efficacy, such as stability and inhibitor evasion.

Main Results:

• RNases exert cytotoxicity through a multi-step process involving cell interaction, internalization, and RNA degradation.
• The precise interplay of factors like thermodynamic stability, catalytic activity, and inhibitor evasion remains incompletely understood.
• Various approaches exist to harness RNases for therapeutic purposes.

Conclusions:

• RNases represent a promising class of anti-cancer agents with potential for clinical application.
• Further research is needed to fully understand and optimize RNase-based cancer therapies.
• Exploiting RNase cytotoxicity offers a novel avenue for developing targeted cancer treatments.